JP2015519890A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015519890A5 JP2015519890A5 JP2015509079A JP2015509079A JP2015519890A5 JP 2015519890 A5 JP2015519890 A5 JP 2015519890A5 JP 2015509079 A JP2015509079 A JP 2015509079A JP 2015509079 A JP2015509079 A JP 2015509079A JP 2015519890 A5 JP2015519890 A5 JP 2015519890A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- natural killer
- culturing
- item
- serum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 63
- 210000000130 stem cell Anatomy 0.000 claims description 33
- 210000000822 natural killer cell Anatomy 0.000 claims description 32
- 238000012258 culturing Methods 0.000 claims description 29
- 239000012679 serum free medium Substances 0.000 claims description 29
- 210000002242 embryoid body Anatomy 0.000 claims description 20
- 210000004027 cell Anatomy 0.000 claims description 19
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 15
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 15
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 11
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 claims description 8
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 claims description 8
- 102000003812 Interleukin-15 Human genes 0.000 claims description 8
- 108090000172 Interleukin-15 Proteins 0.000 claims description 8
- 102000000588 Interleukin-2 Human genes 0.000 claims description 8
- 108010002350 Interleukin-2 Proteins 0.000 claims description 8
- 102000000646 Interleukin-3 Human genes 0.000 claims description 8
- 108010002386 Interleukin-3 Proteins 0.000 claims description 8
- 102000000704 Interleukin-7 Human genes 0.000 claims description 8
- 108010002586 Interleukin-7 Proteins 0.000 claims description 8
- 102000002698 KIR Receptors Human genes 0.000 claims description 8
- 108010043610 KIR Receptors Proteins 0.000 claims description 8
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 8
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 8
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 8
- 229940076264 interleukin-3 Drugs 0.000 claims description 8
- 229940100994 interleukin-7 Drugs 0.000 claims description 8
- 210000002536 stromal cell Anatomy 0.000 claims description 8
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 claims description 7
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 claims description 7
- 238000004220 aggregation Methods 0.000 claims description 7
- 230000002776 aggregation Effects 0.000 claims description 7
- 210000001778 pluripotent stem cell Anatomy 0.000 claims description 7
- 101000608935 Homo sapiens Leukosialin Proteins 0.000 claims description 5
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 5
- 102100039564 Leukosialin Human genes 0.000 claims description 5
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 5
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 5
- 238000003501 co-culture Methods 0.000 claims description 5
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 5
- 239000002609 medium Substances 0.000 claims description 5
- 241000701022 Cytomegalovirus Species 0.000 claims description 4
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 4
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 4
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims description 4
- 101000589305 Homo sapiens Natural cytotoxicity triggering receptor 2 Proteins 0.000 claims description 4
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims description 4
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims description 4
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 4
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 4
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 4
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims description 4
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 claims description 4
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 claims description 4
- 102100032851 Natural cytotoxicity triggering receptor 2 Human genes 0.000 claims description 4
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 4
- 102000036366 SCF complex Human genes 0.000 claims description 4
- 108091007047 SCF complex Proteins 0.000 claims description 4
- 241000700584 Simplexvirus Species 0.000 claims description 4
- 230000004931 aggregating effect Effects 0.000 claims description 4
- 239000003102 growth factor Substances 0.000 claims description 4
- 239000002243 precursor Substances 0.000 claims description 4
- 241000700721 Hepatitis B virus Species 0.000 claims description 3
- 238000009169 immunotherapy Methods 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 230000000415 inactivating effect Effects 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 241000711549 Hepacivirus C Species 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 230000004523 agglutinating effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261637592P | 2012-04-24 | 2012-04-24 | |
| US61/637,592 | 2012-04-24 | ||
| PCT/US2013/037782 WO2013163171A1 (en) | 2012-04-24 | 2013-04-23 | Method for developing natural killer cells from stem cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017115944A Division JP6529541B2 (ja) | 2012-04-24 | 2017-06-13 | 幹細胞よりナチュラルキラー細胞を発生させる方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015519890A JP2015519890A (ja) | 2015-07-16 |
| JP2015519890A5 true JP2015519890A5 (https=) | 2016-06-23 |
| JP6339998B2 JP6339998B2 (ja) | 2018-06-06 |
Family
ID=48289670
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015509079A Active JP6339998B2 (ja) | 2012-04-24 | 2013-04-23 | 幹細胞よりナチュラルキラー細胞を発生させる方法 |
| JP2017115944A Active JP6529541B2 (ja) | 2012-04-24 | 2017-06-13 | 幹細胞よりナチュラルキラー細胞を発生させる方法 |
| JP2019091121A Pending JP2019122415A (ja) | 2012-04-24 | 2019-05-14 | 幹細胞よりナチュラルキラー細胞を発生させる方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017115944A Active JP6529541B2 (ja) | 2012-04-24 | 2017-06-13 | 幹細胞よりナチュラルキラー細胞を発生させる方法 |
| JP2019091121A Pending JP2019122415A (ja) | 2012-04-24 | 2019-05-14 | 幹細胞よりナチュラルキラー細胞を発生させる方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9260696B2 (https=) |
| EP (2) | EP3567102A1 (https=) |
| JP (3) | JP6339998B2 (https=) |
| AU (3) | AU2013251785B2 (https=) |
| WO (1) | WO2013163171A1 (https=) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013163171A1 (en) * | 2012-04-24 | 2013-10-31 | Kaufman Dan S | Method for developing natural killer cells from stem cells |
| WO2014165707A2 (en) | 2013-04-03 | 2014-10-09 | Memorial Sloan-Kettering Cancer Center | Effective generation of tumor-targeted t-cells derived from pluripotent stem cells |
| WO2016123100A1 (en) * | 2015-01-26 | 2016-08-04 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
| WO2016143826A1 (ja) * | 2015-03-09 | 2016-09-15 | 学校法人慶應義塾 | 多能性幹細胞を所望の細胞型へ分化する方法 |
| WO2016187820A1 (zh) * | 2015-05-26 | 2016-12-01 | 中国科学院广州生物医药与健康研究院 | 一种人原代细胞培养基及其应用 |
| PL412787A1 (pl) * | 2015-06-22 | 2017-01-02 | Magdalena Król | Oparty na makrofagach celowany system dostarczania związków związanych z ferrytyną |
| US10736963B2 (en) * | 2015-07-24 | 2020-08-11 | Innate Pharma | Methods for detecting tissue infiltrating NK cells |
| SG11201801770VA (en) * | 2015-09-08 | 2018-04-27 | Sumitomo Dainippon Pharma Co Ltd | Method for producing retinal pigment epithelial cells |
| SG11201803145RA (en) | 2015-11-04 | 2018-05-30 | Fate Therapeutics Inc | Methods and compositions for inducing hematopoietic cell differentiation |
| KR20250141836A (ko) | 2015-11-04 | 2025-09-29 | 페이트 세러퓨틱스, 인코포레이티드 | 만능 세포의 유전자 조작 |
| CN105296428A (zh) * | 2015-12-03 | 2016-02-03 | 广州医科大学附属第三医院 | 一种提高诱导多能干细胞的体外分化造血效率的方法 |
| EP3827838B1 (en) | 2015-12-16 | 2023-06-07 | The Walter and Eliza Hall Institute of Medical Research | Inhibition of cytokine-induced sh2 protein in nk cells |
| US20190161726A1 (en) * | 2016-07-29 | 2019-05-30 | Daikin Industries, Ltd. | Differentiated cell production method and culture bag used therefor |
| US20190194621A1 (en) * | 2016-09-08 | 2019-06-27 | Kyowa Hakko Bio Co., Ltd. | Medium for culturing stem cells, method for culturing stem cells, growth promoter for stem cells, and cell composition and method for producing same |
| EP3580332B1 (en) * | 2017-02-07 | 2026-04-15 | Agency for Science, Technology And Research | Methods and kits for generating mimetic innate immune cells from pluripotent stem cells |
| IL309689B1 (en) * | 2017-02-28 | 2026-02-01 | Univ Central Florida Res Found Inc | PM21 particles to enhance NK cell migration to the bone marrow |
| WO2018164240A1 (ja) | 2017-03-08 | 2018-09-13 | 大日本住友製薬株式会社 | 網膜色素上皮細胞の製造方法 |
| AU2018240416B2 (en) * | 2017-03-21 | 2024-07-11 | Centre National De La Recherche Scientifique | Methods of improving hematopoietic grafts |
| KR102167548B1 (ko) * | 2017-09-21 | 2020-10-19 | 한국생명공학연구원 | 자연살해세포의 제조방법 및 그의 용도 |
| MX2020005907A (es) * | 2017-12-08 | 2020-10-19 | Juno Therapeutics Inc | Formulacion de medio libre de suero para cultivar celulas y metodos de uso de la misma. |
| IL276365B2 (en) | 2018-02-01 | 2023-10-01 | Nkmax Co Ltd | A method for the production of natural killer cells and a preparation for cancer treatment |
| EP3755347B1 (en) * | 2018-02-21 | 2025-06-25 | Board of Regents, The University of Texas System | Universal antigen presenting cells and uses thereof |
| US12473336B2 (en) | 2018-02-21 | 2025-11-18 | Board Of Regents, The University Of Texas System | Methods for activation and expansion of natural killer cells and uses thereof |
| US12516099B2 (en) | 2018-08-09 | 2026-01-06 | Juno Therapeutics, Inc. | Processes for generating engineered cells and compositions thereof |
| CA3109804A1 (en) | 2018-08-16 | 2020-02-20 | The Regents Of The University Of California | Chemically and photochemically initiated cell membrane blebbing to induce cell vesicle production, modifications thereof, and uses thereof |
| HRP20240821T1 (hr) | 2018-08-27 | 2024-09-27 | Affimed Gmbh | Stanice nk čuvane zamrzavanjem, koje su prethodno ubačene uz protutijelni konstrukt |
| AU2019336221B2 (en) | 2018-09-07 | 2025-05-15 | Wisconsin Alumni Research Foundation | Generation of hematopoietic progenitor cells from human pluripotent stem cells |
| WO2020180744A1 (en) * | 2019-03-01 | 2020-09-10 | The Regents Of The University Of California | Natural killer cell induced cellular vesicles for cancer therapy |
| KR102298639B1 (ko) * | 2019-03-28 | 2021-09-07 | 한국생명공학연구원 | 면역세포의 제조방법 및 그의 용도 |
| RU2731293C1 (ru) | 2019-04-12 | 2020-09-01 | Игорь Петрович Белецкий | Способ получения генно-модифицированных линий клеток натуральных киллеров с нокаутированным геном PD-1 и повышенной экспрессией белков семейства Фактора Некроза Опухолей для иммунотерапии онкологических заболеваний |
| WO2020220016A1 (en) * | 2019-04-26 | 2020-10-29 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Artificial antigen presenting cells comprising ligands for nkg2d for expanding immune cells for immunotherapy |
| EP4060024A4 (en) * | 2019-11-13 | 2023-12-06 | Karis Bio Inc. | METHOD FOR ISOLATING PURE CULTURE OF VASCULAR ENDOTHELIAL CELLS, MEDIUM FOR MAINTAINING THE CHARACTERISTICS OF VASCULAR ENDOTHELIAL CELLS, AND CULTURE METHOD COMPRISING SAME |
| CN111235105B (zh) * | 2020-03-06 | 2021-08-10 | 安徽中盛溯源生物科技有限公司 | 一种从人多能干细胞分化为自然杀伤细胞的方法及应用 |
| WO2021183776A1 (en) * | 2020-03-11 | 2021-09-16 | Research Institute At Nationwide Children's Hospital | Nk cells and uses thereof for treatment of microbial infections |
| US11547726B2 (en) | 2020-03-26 | 2023-01-10 | Honed Life Sciences, Llc | Enhancement of production of NK cells from stem cells |
| US20230257705A1 (en) | 2020-06-17 | 2023-08-17 | Kyoto University | Chimeric antigen receptor-expressing immunocompetent cells |
| CN116096858A (zh) * | 2020-07-27 | 2023-05-09 | 加拿大干细胞技术公司 | 用于分化造血细胞的系统和方法 |
| US11459372B2 (en) | 2020-11-30 | 2022-10-04 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| CN112608895B (zh) * | 2020-12-18 | 2024-02-27 | 深圳市济因生物科技有限公司 | 一种人多能干细胞分化的自然杀伤细胞及其制备方法与应用 |
| WO2022144632A1 (en) * | 2020-12-30 | 2022-07-07 | Crispr Therapeutics Ag | Compositions and methods for differentiating stem cells into nk cells |
| EP4326852A4 (en) * | 2021-04-22 | 2025-04-23 | Artec Biotech, Inc. | Method for producing hematopoietic cells from stem cells using vascular organoids |
| WO2022269393A1 (en) | 2021-06-23 | 2022-12-29 | Crispr Therapeutics Ag | Engineered cells with improved protection from natural killer cell killing |
| CN115261318B (zh) * | 2021-09-29 | 2024-05-28 | 苏州艾凯利元生物科技有限公司 | 产生自然杀伤细胞的方法 |
| US20250000974A1 (en) * | 2021-10-27 | 2025-01-02 | The Regents Of The University Of California | Combination of human natural killer cells and macrophages for cancer therapy |
| CN113957048A (zh) * | 2021-10-29 | 2022-01-21 | 深圳市默赛尔生物医学科技发展有限公司 | 一种利用脐带血单个核细胞生产自然杀伤细胞的方法 |
| MX2024007261A (es) | 2021-12-17 | 2024-08-06 | Umoja Biopharma Inc | Celula linfoide innata citotoxica y usos de la misma. |
| TW202346574A (zh) * | 2022-01-31 | 2023-12-01 | 日商希里歐斯股份有限公司 | 自然殺手細胞之製造方法 |
| CN114507641B (zh) * | 2022-04-20 | 2022-07-12 | 山东兴瑞生物科技有限公司 | 一种由人胚胎干细胞诱导分化为nk细胞的方法 |
| WO2023233342A2 (en) | 2022-06-01 | 2023-12-07 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| KR20250022772A (ko) * | 2022-06-09 | 2025-02-17 | 우모자 바이오파마 인코포레이티드 | Nk 세포 분화를 위한 조성물 및 방법 |
| CN115058387B (zh) * | 2022-06-11 | 2023-12-01 | 重庆医科大学 | 一种人胚胎干细胞与前列腺癌细胞共培养制备抗前列腺癌药物的方法 |
| AU2023314782A1 (en) * | 2022-07-27 | 2025-01-30 | Umoja Biopharma, Inc. | Differentiation of stem cells in suspension culture |
| WO2024101863A1 (ko) * | 2022-11-07 | 2024-05-16 | 마루테라퓨틱스 주식회사 | 줄기세포 기원 및 발현 마커에 따른 nk 세포 분화 효율 증진 방법 |
| WO2024101862A1 (ko) * | 2022-11-07 | 2024-05-16 | 마루테라퓨틱스 주식회사 | Nk 세포의 분화 효율 및 기능성 증가를 위한 배양 방법 |
| EP4524241A4 (en) * | 2022-11-10 | 2025-10-08 | Sungkwang Medical Found | MEDIUM COMPOSITION FOR INDUCING DIFFERENTIATION FROM PLURIPOTENT STEM CELLS INTO NATURAL KILLER CELLS AND DIFFERENTIATION METHOD USING SAME |
| AU2024263914A1 (en) * | 2023-04-27 | 2025-12-04 | Takeda Pharmaceutical Company Limited | Method for expanding cd56+/cd3- cells |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0018737B1 (en) | 1979-04-11 | 1983-11-09 | Mitsui Petrochemical Industries, Ltd. | Process for producing spherical carrier particles for olefin polymerisation catalyst, catalyst comprising such carrier particles, and use of such catalyst in olefin polymerisation |
| EP0187371B1 (en) | 1984-12-27 | 1991-06-19 | Asahi Kasei Kogyo Kabushiki Kaisha | Substituted isoquinolinesulfonyl compounds |
| US6355476B1 (en) | 1988-11-07 | 2002-03-12 | Advanced Research And Technologyinc | Nucleic acid encoding MIP-1α Lymphokine |
| CA2214649C (en) | 1995-03-08 | 2007-06-12 | Zeling Cai | Antigen presenting system and methods for activation of t-cells |
| ES2278390T3 (es) | 1996-05-23 | 2007-08-01 | The Scripps Research Institute | Sistema de presentacion de antigenos de clase ii de cmh y procedimientos de activacion de linfocitos t cd4+. |
| CA2277278A1 (en) | 1997-01-10 | 1998-07-16 | Life Technologies, Inc. | Embryonic stem cell serum replacement |
| US6790662B1 (en) | 1999-03-12 | 2004-09-14 | Ortho-Mcneil Pharmaceutical, Inc. | Method of isolating CD8+ cells, and related hybridoma cells antibodies and polypeptides |
| WO2000057913A1 (en) | 1999-03-25 | 2000-10-05 | Welfide Corporation | Preventives/remedies for interstitial pneumonia and pulmonary fibrosis |
| WO2000078351A1 (en) | 1999-06-18 | 2000-12-28 | Mitsubishi Pharma Corporation | Osteogenesis promoters |
| US20040071671A1 (en) | 2001-02-20 | 2004-04-15 | Leturcq Didier J. | Cell therapy method for the treatment of tumors |
| MXPA04007196A (es) | 2002-01-23 | 2005-06-08 | Bayer Pharmaceuticals Corp | Inhibidores de rho-quinasa. |
| US6664266B2 (en) | 2002-03-14 | 2003-12-16 | Children's Medical Center Corporation | Axon regeneration with PKC inhibitiors |
| GB0206860D0 (en) | 2002-03-22 | 2002-05-01 | Glaxo Group Ltd | Compounds |
| JP2005527209A (ja) | 2002-04-22 | 2005-09-15 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 疼痛管理のためのプロテインキナーゼＣγのペプチドインヒビター |
| ATE549395T1 (de) | 2004-09-08 | 2012-03-15 | Wisconsin Alumni Res Found | Medium und kultur von embryonalen stammzellen |
| CA2643337C (en) | 2006-03-01 | 2016-01-12 | Janssen Pharmaceutica N.V. | Cancer treatment combining lymphodepleting agent with ctls and cytokines |
| JP5543207B2 (ja) | 2006-10-04 | 2014-07-09 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 不活性化された人工抗原提示細胞の調製および細胞治療におけるそれらの使用 |
| US8513012B2 (en) | 2008-05-02 | 2013-08-20 | Cellular Dynamics International, Inc. | Method for production of mast cells from stem cells |
| KR101720961B1 (ko) | 2009-02-27 | 2017-03-29 | 셀룰러 다이내믹스 인터내셔널, 인코포레이티드 | 다능성 세포의 분화 |
| CA3080368A1 (en) | 2009-12-04 | 2011-06-09 | Stem Cell & Regenerative Medicine International, Inc. | Method of generating natural killer cells and dendritic cells from human embryonic stem cell-derived hemangioblasts |
| WO2013163171A1 (en) * | 2012-04-24 | 2013-10-31 | Kaufman Dan S | Method for developing natural killer cells from stem cells |
-
2013
- 2013-04-23 WO PCT/US2013/037782 patent/WO2013163171A1/en not_active Ceased
- 2013-04-23 AU AU2013251785A patent/AU2013251785B2/en not_active Ceased
- 2013-04-23 JP JP2015509079A patent/JP6339998B2/ja active Active
- 2013-04-23 EP EP19179319.9A patent/EP3567102A1/en not_active Withdrawn
- 2013-04-23 US US13/868,785 patent/US9260696B2/en active Active
- 2013-04-23 EP EP13720688.4A patent/EP2841563B1/en active Active
-
2017
- 2017-06-13 JP JP2017115944A patent/JP6529541B2/ja active Active
-
2018
- 2018-07-18 AU AU2018206749A patent/AU2018206749A1/en not_active Abandoned
-
2019
- 2019-05-14 JP JP2019091121A patent/JP2019122415A/ja active Pending
-
2020
- 2020-11-06 AU AU2020264375A patent/AU2020264375B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015519890A5 (https=) | ||
| JP7440027B2 (ja) | 多能性幹細胞から免疫細胞療法用ｔ細胞を誘導する方法 | |
| JP6529541B2 (ja) | 幹細胞よりナチュラルキラー細胞を発生させる方法 | |
| JP6948072B2 (ja) | Ｃｄ８陽性ｔ細胞を誘導する方法 | |
| CN102329769B (zh) | 一种获得造血干细胞的方法 | |
| Knorr et al. | Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy | |
| Sun et al. | Early transduction produces highly functional chimeric antigen receptor-modified virus-specific T-cells with central memory markers: a production assistant for cell therapy (PACT) translational application | |
| CN107922925A (zh) | 用于自然杀伤细胞扩增的方法 | |
| US7811821B2 (en) | Method of forming dendritic cells from embryonic stem cells | |
| Ni et al. | Hematopoietic and nature killer cell development from human pluripotent stem cells | |
| TW201900872A (zh) | 高活性nk細胞及其利用 | |
| WO2015099134A1 (ja) | 再構成されたｔ細胞レセプター遺伝子を有する多能性幹細胞由来のｔ前駆細胞を用いる免疫細胞療法 | |
| KR102803233B1 (ko) | 조혈 전구 세포 마커 | |
| US11299709B2 (en) | Pluripotent stem cell and T cell differentiated therefrom and application thereof | |
| JPWO2016010153A1 (ja) | 免疫細胞療法用ｔ細胞の誘導方法 | |
| CN115087732B (zh) | 来自人T细胞来源的iPS细胞的细胞毒性T细胞 | |
| KR101390613B1 (ko) | Ｓｅｌｅｎｉｕｍ을 이용한 인간 만능줄기세포의 혈액전구세포, 혈관전구세포, 내피세포 및 평활근세포로의 분화방법 | |
| Moon et al. | Differentiation of hESCs into mesodermal subtypes: vascular-, hematopoietic-and mesenchymal-lineage cells | |
| TW200540270A (en) | Medium for feeder-free differentiation and feeder-free differentiation method from primate embryonic stem cell | |
| JP2024518632A (ja) | 体液免疫系の再生方法およびその使用 | |
| CN115418373A (zh) | 一种体液免疫系统再生的方法及其应用 | |
| Ma | Derivation of Lymphocytes from Human induced Pluripotent Stem Cells | |
| Gori et al. | Blood First Edition Paper, prepublished online August 16, 2012; DOI 10.1182/blood-2012-05-433797 | |
| EA045419B1 (ru) | Маркер гемопоэтических клеток-предшественников |